Apogee Therapeutics Inc [APGE] stock prices are up 1.57% to $82.04 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APGE shares have gain 5.65% over the last week, with a monthly amount glided 8.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stephens started tracking the stock with Overweight rating on December 17, 2025, and set its price target to $95. On December 10, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $103 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $109 on November 03, 2025. Mizuho initiated its recommendation with a Outperform and recommended $105 as its price target on October 21, 2025. RBC Capital Mkts started tracking with a Outperform rating for this stock on September 25, 2025, and assigned it a price target of $60. In a note dated July 07, 2025, BTIG Research reiterated an Buy rating on this stock and boosted its target price from $100 to $115.
The stock price of Apogee Therapeutics Inc [APGE] has been fluctuating between $26.20 and $84.56 over the past year. Currently, Wall Street analysts expect the stock to reach $107.33 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $82.04 at the most recent close of the market. An investor can expect a potential return of 30.83% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.39 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Apogee Therapeutics Inc [NASDAQ:APGE]’s Current Ratio is 15.86. As well, the Quick Ratio is 15.86, while the Cash Ratio is 3.17.
Transactions by insiders
Recent insider trading involved HENDERSON MICHAEL THOMAS, Chief Executive Officer, that happened on Jan 14 ’26 when 20000.0 shares were sold. Chief Medical Officer, Dambkowski Carl completed a deal on Jan 07 ’26 to sell 18700.0 shares. Meanwhile, Officer CARL DAMBKOWSKI bought 35200.0 shares on Jan 07 ’26.
